DrugPatentWatch Database Preview

Details for Patent: 6,727,256

« Back to Dashboard

Which drugs does patent 6,727,256 protect, and when does it expire?

Patent 6,727,256 protects TYKERB and is included in one NDA.

This patent has seventy patent family members in forty-six countries.

Summary for Patent: 6,727,256

Title:	Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
Abstract:	Substituted heteroaromatic compounds of formula (I), wherein X is N or CH; Y is CR.sup.1 and V is N; or Y is N and V is CR.sup.1 ; or Y is CR.sup.1 and V is CR.sup.2 ; or Y is CR.sup.2 and V is CR.sup.1 ; R.sup.1 represents a group CH.sub.3 SO.sub.2 CH.sub.2 CH.sub.2 NHCH.sub.2 --Ar--, wherein Ar is selected from phenyl, furan, thiophene, pyrrole and thiazole, each of which may optionally be substituted by one or two halo, C.sub.1-4 alkyl or C.sub.1-4 alkoxy groups; R.sup.2 is selected from the group comprising hydrogen, halo, hydroxy, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkylamino and di[C.sub.1-4 alkyl]amino; U represents a phenyl, pyridyl, 3H-imidazolyl, indolyl, isoindolyl, indolinyl, isoindolinyl, 1H-indazolyl, 2,3-dihydro-1H-indazolyl, 1H-benzimidazolyl, 2,3-dihydro-1H-benzimidazolyl or 1H-benzotriazolyl group, substituted by an R.sup.3 group and optionally substituted by at least one independently selected R.sup.4 group; R.sup.3 is selected from a group comprising benzyl, halo-, dihalo- and trihalobenzyl, benzoyl, pyridylmethyl, pyridylmethoxy, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl, or R.sup.3 represents trihalomethylbenzyl or trihalomethylbenzyloxy; or R.sup.3 represents a group of formula (a) wherein each R.sup.5 is independently selected from halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy; and n is 0 to 3; each R.sup.4 is independently hydroxy, halogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, C.sub.1-4 alkoxy, amino, C.sub.1-4 alkylamino, di[C.sub.1-4 alkyl]amino, C.sub.1-4 alkylthio, C.sub.1-4 alkylsulphinyl, C.sub.1-4 alkylsulphonyl, C.sub.1-4 alkylcarbonyl, carboxy, carbamoyl, C.sub.1-4 alkoxycarbonyl, C.sub.1-4 alkanoylamino, N-(C.sub.1-4 alkyl)carbamoyl, N,N-di(C.sub.1-4 alkyl)carbamoyl, cyano, nitro and trifluoromethyl; and salts and solvates thereof, are disclosed, as are methods for their preparation, pharmaceutical compositions containing them and their use in medicine.
Inventor(s):	Carter; Malcolm Clive (Ware, GB), Cockerill; George Stuart (Bedford, GB), Guntrip; Stephen Barry (Hertford, GB), Lackey; Karen Elizabeth (Hillsborough, NC), Smith; Kathryn Jane (Bishop's Stortford, GB)
Assignee:	SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:	09/582,746
Patent Claim Types: see list of patent claims	Compound; Composition; Dosage form; Use;

Drugs Protected by US Patent 6,727,256

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Novartis Pharms Corp	TYKERB	lapatinib ditosylate	TABLET;ORAL	022059-001	Mar 13, 2007		RX	Yes	Yes			Y	Y		TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB
Novartis Pharms Corp	TYKERB	lapatinib ditosylate	TABLET;ORAL	022059-001	Mar 13, 2007		RX	Yes	Yes			Y	Y		TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR

Foreign Priority and PCT Information for Patent: 6,727,256

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9800569	Jan 12, 1998

PCT Information
PCT Filed	January 08, 1999	PCT Application Number:	PCT/EP99/00048
PCT Publication Date:	July 15, 1999	PCT Publication Number:	WO99/35146

Non-Orange Book US Patents Family Members for Patent 6,727,256

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,912,205	Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
6,713,485	Heterocyclic compounds
9,199,973	Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
8,513,262	Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

International Family Members for US Patent 6,727,256

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	1446
Argentina	015507
Argentina	066982
Austria	270670